DK1427403T3 - Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling - Google Patents

Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Info

Publication number: DK1427403T3
Authority: DK; Denmark
Prior art keywords: cancer; treatment; combination; radiation; head
Prior art date: 2001-09-18

Application number

DK02777129T

Other languages

Danish (da)

English (en)

Inventor

Bernd Groner

Bernd Hentsch

Peter A Herrlich

Pier Giuseppe Pelicci

Martin Goettlicher

Thorsten Heinzel

Winfried Stephan Wels

Saverio Minucci

Original Assignee

Topotarget Germany Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-18

Filing date

2002-09-17

Publication date

2006-04-03

2002-09-17 Application filed by Topotarget Germany Ag filed Critical Topotarget Germany Ag

2006-04-03 Application granted granted Critical

2006-04-03 Publication of DK1427403T3 publication Critical patent/DK1427403T3/da

Links

NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
208000000587 small cell lung carcinoma Diseases 0.000 title 2
206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
206010009944 Colon cancer Diseases 0.000 title 1
206010041067 Small cell lung cancer Diseases 0.000 title 1
210000000601 blood cell Anatomy 0.000 title 1
208000029742 colonic neoplasm Diseases 0.000 title 1
201000010536 head and neck cancer Diseases 0.000 title 1
208000014829 head and neck neoplasm Diseases 0.000 title 1
230000005855 radiation Effects 0.000 title 1
229960000604 valproic acid Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000003964 Histone deacetylase Human genes 0.000 abstract 1
108090000353 Histone deacetylase Proteins 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
208000007660 Residual Neoplasm Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
229940126585 therapeutic drug Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK02777129T 2001-09-18 2002-09-17 Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling DK1427403T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01121722A EP1293205A1 (de)	2001-09-18	2001-09-18	Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung

Publications (1)

Publication Number	Publication Date
DK1427403T3 true DK1427403T3 (da)	2006-04-03

Family

ID=8178602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02777129T DK1427403T3 (da)	2001-09-18	2002-09-17	Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Country Status (11)

Country	Link
US (1)	US20050038113A1 (de)
EP (4)	EP1293205A1 (de)
JP (1)	JP2005512961A (de)
AT (1)	ATE314063T1 (de)
AU (1)	AU2002338716B2 (de)
CA (1)	CA2460713A1 (de)
CY (1)	CY1105552T1 (de)
DE (1)	DE60208397T2 (de)
DK (1)	DK1427403T3 (de)
ES (1)	ES2252519T3 (de)
WO (1)	WO2003024442A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7250514B1 (en)	2002-10-21	2007-07-31	Takeda San Diego, Inc.	Histone deacetylase inhibitors
KR20050122210A (ko) *	2003-03-17	2005-12-28	다케다 샌디에고, 인코포레이티드	히스톤 탈아세틸화 효소 억제제
MXPA05012464A (es) *	2003-05-21	2006-01-30	Novartis Ag	Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (de)	2003-06-25	2004-12-29	G2M Cancer Drugs AG	Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
JP2007504131A (ja) *	2003-08-29	2007-03-01	エートンファーマインコーポレーティッド	癌の組み合わせ処置法
WO2005065681A1 (en) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7951780B2 (en)	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent
JP2008524246A (ja)	2004-12-16	2008-07-10	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
EP2946810A1 (de)	2005-02-03	2015-11-25	TopoTarget UK Limited	Kombinationstherapie mit einem HDAC-Hemmer und Vincristin zur Behandlung von Krebs
US7869590B2 (en) *	2005-04-12	2011-01-11	Broadcom Corporation	Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets
WO2006122319A2 (en) *	2005-05-11	2006-11-16	Takeda San Diego, Inc.	Histone deacetylase inhibitors
CN102579417B (zh)	2005-05-13	2014-11-26	托波塔吉特英国有限公司	Hdac抑制剂的药物制剂
ZA200800901B (en)	2005-07-14	2010-05-26	Takeda San Diego Inc	Histone deacetylase inhibitors
EP2361619A1 (de)	2005-11-10	2011-08-31	TopoTarget UK Limited	Histone Deacetylase (hdac) Inhibitoren (pxd-101) zur Behandlung von hämatologischen Krebserkrankungen
BRPI0520686A2 (pt) *	2005-11-16	2009-05-19	Univ Mexico Nacional Autonoma	uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
RU2389484C2 (ru) *	2005-11-18	2010-05-20	Универсидад Насиональ Аутонома Де Мексико	Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака
WO2007084390A2 (en) *	2006-01-13	2007-07-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
JP5113038B2 (ja) *	2006-03-23	2013-01-09	テムリック株式会社	癌治療用キットおよび癌治療用医薬組成物
CA2649877A1 (en)	2006-04-24	2007-12-21	Gloucester Pharmaceuticals	Gemcitabine combination therapy
DE102006022877B4 (de)	2006-05-15	2009-01-29	Sartorius Stedim Biotech Gmbh	Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
WO2007146730A2 (en)	2006-06-08	2007-12-21	Gloucester Pharmaceuticals	Deacetylase inhibitor therapy
CA2661024A1 (en) *	2006-08-28	2008-03-06	The Regents Of The University Of California	Small molecule potentiator of hormonal therapy for breast cancer
EP2091525A1 (de) *	2006-12-06	2009-08-26	Sapporo Medical University	Verstärkung der zellimmunität mit histon-deacetylase (hdac)-hemmern
GB0625283D0 (en) *	2006-12-19	2007-01-24	Cyclacel Ltd	Combination
JP2010514801A (ja)	2006-12-29	2010-05-06	グラスターファーマシューティカルズ，インコーポレイテッド	ロミデプシンの精製
CA2726734C (en) *	2007-06-06	2014-10-07	University Of Maryland, Baltimore	Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
CA2700173C (en)	2007-09-25	2016-10-11	Topotarget Uk Limited	Methods of synthesis of certain hydroxamic acid compounds
WO2010064422A1 (ja) *	2008-12-02	2010-06-10	静岡県公立大学法人	ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
US8491927B2 (en)	2009-12-02	2013-07-23	Nimble Epitech, Llc	Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
MX342913B (es)	2010-07-12	2016-10-19	Celgene Corp *	Formas solidas de romidepsina y sus usos.
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
KR101733189B1 (ko)	2010-10-06	2017-05-08	(주)아모레퍼시픽	손톱 또는 발톱 성장 촉진용 조성물
DK2688572T3 (en) *	2011-03-21	2017-06-12	Valcuria Ab	PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
AU2013202506B2 (en)	2012-09-07	2015-06-18	Celgene Corporation	Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en)	2012-11-14	2015-08-13	Celgene Corporation	Inhibition of drug resistant cancer cells
NZ630311A (en)	2013-12-27	2016-03-31	Celgene Corp	Romidepsin formulations and uses thereof
JP6551963B2 (ja) *	2014-05-14	2019-07-31	国立大学法人京都大学	巨核球前駆細胞の製造方法
KR102567244B1 (ko) *	2014-06-12	2023-08-16	세다르스-신나이 메디칼 센터	암을 치료하는 조성물 및 방법
GB202102606D0 (en) *	2021-02-24	2021-04-07	Univ Oxford Innovation Ltd	Treatment of ovarian cancer minimal residual disease
WO2023008459A1 (ja) *	2021-07-27	2023-02-02	東レ株式会社	癌の治療及び／又は予防のための医薬品

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4935450A (en) *	1982-09-17	1990-06-19	Therapeutical Systems Corporation	Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1339034C (en) *	1988-08-22	1997-04-01	Paul A. Tremblay	Platinum complexes of single isomer neoalkyl acids
JPH0279969A (ja) *	1988-09-19	1990-03-20	Shigeyoshi Fujimoto	細胞障害性ｔ細胞誘導及び活性化の方法
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
TW248552B (de) *	1993-06-01	1995-06-01	Onoda Yakuhin Kogyo Kk
US6300373B1 (en) *	1993-09-10	2001-10-09	American Biogenetic Sciences, Inc.	Antiproliferative and neurotrophic molecules
US5672746A (en) *	1994-08-30	1997-09-30	American Biogenetic Sciences, Inc.	Antiproliferative and neurotrophic molecules
US5786344A (en) *	1994-07-05	1998-07-28	Arch Development Corporation	Camptothecin drug combinations and methods with reduced side effects
DE69718029T2 (de) *	1996-10-11	2003-10-16	The Regents Of The University Of California, Oakland	Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6110970A (en) *	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US6124495A (en) *	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6110955A (en) *	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6043389A (en) *	1997-03-11	2000-03-28	Mor Research Applications, Ltd.	Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5939455A (en) *	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6028102A (en) *	1998-02-24	2000-02-22	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Anticonvulsant drugs and pharmaceutical compositions thereof
EP1244461A2 (de) *	1999-12-23	2002-10-02	The Ontario Cancer Institute	Inhibition der gsk-3 beta
EP1170008A1 (de) *	2000-07-07	2002-01-09	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase

2001
- 2001-09-18 EP EP01121722A patent/EP1293205A1/de not_active Withdrawn
2002
- 2002-09-17 DE DE60208397T patent/DE60208397T2/de not_active Expired - Lifetime
- 2002-09-17 DK DK02777129T patent/DK1427403T3/da active
- 2002-09-17 EP EP02777129A patent/EP1427403B8/de not_active Expired - Lifetime
- 2002-09-17 WO PCT/EP2002/010419 patent/WO2003024442A2/en not_active Ceased
- 2002-09-17 JP JP2003528538A patent/JP2005512961A/ja active Pending
- 2002-09-17 EP EP05101081A patent/EP1529527A3/de not_active Withdrawn
- 2002-09-17 AU AU2002338716A patent/AU2002338716B2/en not_active Ceased
- 2002-09-17 CA CA002460713A patent/CA2460713A1/en not_active Abandoned
- 2002-09-17 ES ES02777129T patent/ES2252519T3/es not_active Expired - Lifetime
- 2002-09-17 AT AT02777129T patent/ATE314063T1/de active
- 2002-09-17 US US10/489,770 patent/US20050038113A1/en not_active Abandoned
- 2002-09-17 EP EP05019659A patent/EP1602371A3/de not_active Withdrawn
2006
- 2006-02-28 CY CY20061100277T patent/CY1105552T1/el unknown

Also Published As

Publication number	Publication date
US20050038113A1 (en)	2005-02-17
ATE314063T1 (de)	2006-01-15
EP1427403B8 (de)	2006-03-22
AU2002338716B2 (en)	2007-08-16
CY1105552T1 (el)	2010-07-28
DE60208397T2 (de)	2006-07-13
EP1602371A2 (de)	2005-12-07
ES2252519T3 (es)	2006-05-16
EP1529527A2 (de)	2005-05-11
WO2003024442A2 (en)	2003-03-27
EP1529527A3 (de)	2005-05-25
DE60208397D1 (de)	2006-02-02
CA2460713A1 (en)	2003-03-27
EP1293205A1 (de)	2003-03-19
JP2005512961A (ja)	2005-05-12
EP1602371A3 (de)	2006-11-15
WO2003024442A3 (en)	2003-09-18
EP1427403A2 (de)	2004-06-16
EP1427403B1 (de)	2005-12-28

Publication	Publication Date	Title
ATE314063T1 (de)	2006-01-15	Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
HUP0402217A2 (hu)	2005-01-28	Platinaszármazékot tartalmazó gyógyászati készítmények
MX2007004882A (es)	2007-05-09	Derivados de xantina con actividad de receptor de hm74a.
DE50310516D1 (de)	2008-10-30	Fredericamycin-derivate
NO20015584L (no)	2002-01-03	Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
AR050713A1 (es)	2006-11-15	Uso de una neurotoxina botulinica para la preparacion de un medicamento para el tratamiento de un cancer
EA200501570A1 (ru)	2006-06-30	Новые гидроксаматы как лечебные средства
NO20072931L (no)	2007-08-03	Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
WO2005016867A3 (en)	2005-03-31	Anthranilic acid derivatives and their use as activators of the hm74a receptor
HRP20040944B1 (en)	2012-12-31	Medicaments containing betamimetic drugs and a novel anticholinesterase drug
RU2007145489A (ru)	2009-06-20	Фармацевтические композиции и способы лечения рака и его метастазов
PT2111868E (pt)	2013-10-17	Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
DE60229767D1 (de)	2008-12-18	Verwendung von laminarin in der behandlung von krebs
NO20043792L (no)	2005-01-04	New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE60330914D1 (de)	2010-02-25	Arzneimittel mit shikonin als wirkstoff
ATE535237T1 (de)	2011-12-15	Verwendung von fts zur behandlung von malignen erkrankungen
PL1653964T3 (pl)	2009-01-30	Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no)	2006-10-20	Kombinasjonsterapi
EA200401454A1 (ru)	2005-06-30	Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
EE200200549A (et)	2004-02-16	Jagatud doosi teraapia veresooni kahjustava aktiivsusega
GT200600210A (es)	2007-01-03	Terapia genica de interferon-beta usdando un sistema mejorado de expresion regulada
IL153586A0 (en)	2003-07-06	Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
Keppler et al.	2019	Metallodrug Strategies in a Changing Environment of Anticancer Drug Development
신현정 et al.	2006	Effect of green tea catechins on the expression and activity of MMPs and type I procollagen synthesis in human dermal fibroblasts